Other

Alfa Laval Corporation Ab

Alfa-Laval Agri International Ab

Torkel Mikael Wadstrom

Magnus Hook

Lars Christer Signas

Martin K Lindberg

Gunnar Froman

Kjell Martin Lindberg

The invention is concerned with a vaccine composition comprising an effective amount of an isolated protein derived from Staphylococcal aureus having the ability to bind fibronectin. The protein has a molecular weight of 165,000 daltons and optionally also contains a protein having a molecular weight of 87,000 daltons. The protein has the ability to elicit antibody production and a level of protein to elicit antibody production. The level of protein is sufficient to produce protection upon challenge with a Staphylococcus aureus bacterial strain in a mammal, particularly a ruminant, by forming antibodies against the Staphylococcus aureus bacterial strain.

Bacterial cell surface protein with fibronectin, fibrinogen, collagen

The present invention relates to a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

Fibronectin binding protein as well as its preparation

The present invention relates to a new recombinant hybrid-DNA-molecule comprising nucleotide sequence from S. aureus coding for a protein, or polypeptide, having fibronectin binding properties.

A method for prophylactic treatments of the colonization of a Staphylococcus aureus bacterial strain having the ability to bind to fibronectin in a mammal. The method comprises administering a prophylactic therapeutically active amount of a protein having fibronectin binding properties to a mammal in need of such treatment. The generation of infections, such as mastitis, caused by a Staphylococcus aureus bacterial strain are thereby prevented. The administration may be via vaccination to induce immunization.

Growing community of inventors

Lund, Sweden

Torkel Mikael Wadstrom